The treatment landscape for triple-negative breast cancer (TNBC) has shifted dramatically with the introduction of immune checkpoint inhibitors (ICI). However, the specific clinical benefits of immunotherapy in older TNBC patients remain a subject of intense scrutiny. Since older adults are often underrepresented in pivotal trials, understanding their specific response rates is essential for tailored care. A recent systematic review analyzed results from 11 randomized controlled trials to address this evidence gap and guide clinical decision-making.

Evidence for Immunotherapy in Older TNBC

The review identified only four trials that reported outcomes specifically for patients aged 65 and older. These trials included KEYNOTE-355, KEYNOTE-522, IMpassion130, and IMpassion131. Across these studies, pembrolizumab showed a positive but nonsignificant trend toward better pathological complete response (pCR) in early-stage disease. Furthermore, in metastatic settings, older patients with high PD-L1 expression (CPS ≥ 10) may experience significantly improved overall survival. Consequently, the data suggests potential benefits even though small sample sizes often limit the statistical power of these findings.

Clinical Implications and Research Gaps

Clinicians must carefully weigh the potential benefits of immunotherapy in older TNBC against the risk of immune-related adverse events. Currently, most studies lack prespecified age-stratified analyses. This lack of data makes it difficult to form definitive clinical guidelines for the geriatric population. Therefore, future research must focus on enrolling more elderly participants to ensure safety and efficacy are well-understood. Additionally, evaluating quality-of-life metrics alongside survival data remains a high priority for managing older patients effectively in Indian oncology practice.

Frequently Asked Questions

Is pembrolizumab effective for elderly patients with TNBC?

Recent systematic reviews indicate that pembrolizumab shows a trend toward improving survival and response rates in older adults. However, results are often statistically nonsignificant due to the low number of trial participants over age 65.

How does PD-L1 status affect treatment in older adults?

In the metastatic setting, a combined positive score (CPS) of 10 or higher is associated with better overall survival outcomes. This suggests that PD-L1 testing is a crucial step for determining which older patients will benefit most from ICI therapy.

Why is there limited data on immunotherapy for the elderly?

Older adults comprise only a small fraction, approximately 18.7%, of clinical trial participants. Furthermore, most trials do not plan for age-specific analysis, leading to a significant knowledge gap in geriatric oncology.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Sha C et al. Efficacy of immunotherapy in older adults with triple-negative breast cancer: A systematic review. J Geriatr Oncol. 2026 Jun 15. doi: undefined. PMID: 42296569.


2. Schmid P et al. Neoadjuvant Pembrolizumab or Placebo plus Chemotherapy followed by Adjuvant Pembrolizumab or Placebo for Early-Stage Triple-Negative Breast Cancer: Final Analysis of Overall Survival from the Phase 3 KEYNOTE-522 Study. N Engl J Med. 2024.


3. Cortes J et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020.